Investigation of Radiolabeling Efficacy by Enhancement of the Chemical form of no Carrier Added Lu Isolated by Electro Amalgamation Process.

Background: Due to the suitable nuclear decay characteristics, Lu is an attractive radionuclide for various therapeutic applications. The non-carrier added form ofLu has drawn much attention because of its high specific activity needed in radiolabeling studies. There have been several separation methods for NCALu production.

Neutronic and thermal-hydraulic analysis of fission molybdenum-99 production at Tehran Research Reactor using LEU plate targets.

Efficient and safe production of molybdenum-99 (Mo) radiopharmaceutical at Tehran Research Reactor (TRR) via fission of LEU targets is studied. Neutronic calculations are performed to evaluate produced Mo activity, core neutronic safety parameters and also the power deposition values in target plates during a 7 days irradiation interval. Thermal-hydraulic analysis has been also carried out to obtain thermal behavior of these plates.

Preliminary dosimetry of (166)Ho-propylene di-amino tetra (methy1enephosphonicacid) for human based on biodistribution data in rats.

Context: Nowadays, radionuclides with high β- particle energies such as (166)Ho are recommended for bone marrow ablation in patients with multiple myeloma. The addition of skeletal targeted radiotherapy to the patients can improve the response rate in phase I and II trials, with promising long-term survival data.

Aims: In this work, the absorbed dose to each organ of human for (166)Ho-propylene di-amino tetra methy1enephosphonicacid (PDTMP) was evaluated based on biodistribution studies in rats and was compared with (166)Ho-tetraazacyclododecane tetramethylene-phosphonate (DOTMP) as the only clinically used Ho-166 bone marrow ablative agent.

Production, biodistribution, and dosimetry of (47)Sc-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid as a bone-seeking radiopharmaceutical.

In this study 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid (DOTMP) was used as the polyaminophosphonic acid carrier ligand and the therapeutic potential of the bone seeking radiopharmaceutical (47)Sc-DOTMP was assessed by measuring its dosage-dependent skeletal uptake and then the absorbed radiation dose of human organs was estimated. Because of limited availability of (47)Sc we performed some preliminary studies using (46)Sc. (46)Sc was produced with a specific activity of 116.

Study of Bone Surface Absorbed Dose in Treatment of Bone Metastases via Selected Radiopharmaceuticals: Using MCNP4C Code and Available Experimental Data.

Bone metastases are major clinical concern that can cause severe problems for patients. Currently, various beta emitters are used for bone pain palliation. This study, describes the process for absorbed dose prediction of selected bone surface and volume-seeking beta emitter radiopharmaceuticals such as (32)P, (89)SrCl2,(90)Y-EDTMP,(153)Sm-EDTMP, (166)Ho-DOTMP, (177)Lu-EDTMP,(186)Re-HEDP, and (188)Re-HEDP in human bone, using MCNP code.